Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1654MCG

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | |
|---|---|---|
| NEWS 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS 2 | AUG 10 | Time limit for inactive STN sessions doubles to 40 minutes |
| NEWS 3 | AUG 18 | COMPENDEX indexing changed for the Corporate Source (CS) field |
| NEWS 4 | AUG 24 | ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced |
| NEWS 5 | AUG 24 | CA/CAplus enhanced with legal status information for U.S. patents |
| NEWS 6 | SEP 09 | 50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY |
| NEWS 7 | SEP 11 | WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus |
| NEWS 8 | OCT 21 | Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded |
| NEWS 9 | OCT 21 | Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models |
| NEWS 10 | NOV 23 | Addition of SCAN format to selected STN databases |
| NEWS 11 | NOV 23 | Annual Reload of IFI Databases |
| NEWS 12 | DEC 01 | FRFULL Content and Search Enhancements |
| NEWS 13 | DEC 01 | DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets |
| NEWS 14 | DEC 02 | Derwent World Patent Index: Japanese FI-TERM thesaurus added |
| NEWS 15 | DEC 02 | PCTGEN enhanced with patent family and legal status display data from INPADOCDB |
| NEWS 16 | DEC 02 | USGENE: Enhanced coverage of bibliographic and sequence information |
| NEWS 17 | DEC 21 | New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAplus |
| NEWS 18 | JAN 12 | Match STN Content and Features to Your Information Needs, Quickly and Conveniently |
| NEWS 19 | JAN 25 | Annual Reload of MEDLINE database |
| NEWS 20 | FEB 16 | STN Express Maintenance Release, Version 8.4.2, Is Now Available for Download |
| NEWS 21 | FEB 16 | Derwent World Patents Index (DWPI) Revises Indexing of Author Abstracts |
| NEWS 22 | FEB 16 | New FASTA Display Formats Added to USGENE and PCTGEN |
| NEWS 23 | FEB 16 | INPADOCDB and INPAFAMDB Enriched with New Content and Features |
| NEWS 24 | FEB 16 | INSPEC Adding Its Own IPC codes and Author's E-mail Addresses |

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 15 JANUARY 2010.

```
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:35:17 ON 07 MAR 2010

=> file registry
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.32       1.32

FILE 'REGISTRY' ENTERED AT 13:38:37 ON 07 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    5 MAR 2010  HIGHEST RN 1208066-55-0
DICTIONARY FILE UPDATES:   5 MAR 2010  HIGHEST RN 1208066-55-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> egtftsdvssylegqaakefiawlvkgrr/sqsp
L1          14 EGTFTSDVSSYLEGQAAKEFIAWLVKGRR/SQSP

=> d ibib sqide 1-14

L1   ANSWER 1 OF 14  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   1025170-10-8  REGISTRY
CN   L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-
     phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-
     L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-
     L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-
     tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl-L-
     arginyl-  (CA INDEX NAME)
OTHER NAMES:
```

CN  4: PN: WO2008056726 SEQID: 5 claimed protein
FS  PROTEIN SEQUENCE
SQL  34

PATENT ANNOTATIONS (PNTE):

| Sequence Source | Patent Reference |
|---|---|
| Not Given | WO2008056726 claimed SEQID 5 |

SEQ  1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRRR
       ======== ========== ========== =
HITS AT:  3-31

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
MF  Unspecified
CI  MAN
SR  CA
LC  STN Files:  CA, CAPLUS
DT.CA  CAplus document type:  Patent
RL.P  Roles from patents:  BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
        1 REFERENCES IN FILE CA (1907 TO DATE)
        1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE  1

ACCESSION NUMBER:  148:554092  CA
TITLE:  Glp-1 derivative and use thereof
INVENTOR(S):  Jomori, Takahito; Hayashi, Yuji; Makino, Mitsuhiro
PATENT ASSIGNEE(S):  Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE:  PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DOCUMENT TYPE:  Patent
LANGUAGE:  Japanese
FAMILY ACC. NUM. COUNT:  2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2008056726 | A1 | 20080515 | WO 2007-JP71687 | 20071108 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| JP 2010043001 | A | 20100225 | JP 2006-304380 | 20061109 |

PRIORITY APPLN. INFO.:  JP 2006-304380  20061109
REFERENCE COUNT:  46  THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1  ANSWER 2 OF 14  REGISTRY  COPYRIGHT 2010 ACS on STN

RN  856221-77-7  REGISTRY
CN  L-Arginine, L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-acetyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-N6-acetyl-L-lysylglycyl-L-arginyl-  (CA INDEX NAME)
OTHER NAMES:
CN  11: PN: WO2005060986 SEQID: 11 claimed protein
FS  PROTEIN SEQUENCE; STEREOSEARCH
SQL  29
NTE  modified (modifications unspecified)

| type | ------ location ------ | | description |
|---|---|---|---|
| modification | Lys-18 | - | acetyl<Ac> |
| modification | Lys-26 | - | acetyl<Ac> |

PATENT ANNOTATIONS (PNTE):

| Sequence Source | Patent Reference |
|---|---|
| Not Given | WO2005060986 claimed SEQID 11 |

SEQ  1 EGTFTSDVSS YLEGQAAKEF IAWLVKGRR
HITS AT:  1-29

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
MF  C150 H229 N39 O47
SR  CA
LC  STN Files:  CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P  Roles from patents:  BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.





PAGE 1-B



PAGE 1-C





**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 149:260057 CA
TITLE: GLP-1 (9-36) and its variants for inhibiting hyperglycemia or free fatty acid-induced reactive oxygen formation in mammalian cells and thereby preventing disease
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Yeshiva University, USA; Albert Einstein College of Medicine
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 582,116.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20080194483 | A1 | 20080814 | US 2008-8362 | 20080110 |
| WO 2005060986 | A1 | 20050707 | WO 2004-US40852 | 20041207 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20080015144 | A1 | 20080117 | US 2007-582116 | 20070626 |

PRIORITY APPLN. INFO.: US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626

REFERENCE 2

ACCESSION NUMBER: 143:91055 CA
TITLE: Glp-1 (9-36) methods and compositions
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Albert Einstein College of Medicine of Yeshiva University, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005060986 | A1 | 20050707 | WO 2004-US40852 | 20041207 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2550217 | A1 | 20050707 | CA 2004-2550217 | 20041207 |
| EP 1701731 | A1 | 20060920 | EP 2004-813201 | 20041207 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| US 20080015144 | A1 | 20080117 | US 2007-582116 | 20070626 |
| US 20080194483 | A1 | 20080814 | US 2008-8362 | 20080110 |

PRIORITY APPLN. INFO.: US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 856221-75-5 REGISTRY
CN L-Arginine, L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-N6-acetyl-L-lysylglycyl-L-arginyl- (CA INDEX NAME)
OTHER NAMES:
CN 9: PN: WO2005060986 SEQID: 9 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 29
NTE modified (modifications unspecified)

| type | location | | description |
|---|---|---|---|
| modification | Lys-26 | - | acetyl<Ac> |

PATENT ANNOTATIONS (PNTE):

| Sequence Source | Patent Reference |
|---|---|
| Not Given | WO2005060986 claimed SEQID 9 |

SEQ 1 EGTFTSDVSS YLEGQAAKEF IAWLVKGRR

HITS AT: 1-29

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

MF C148 H227 N39 O46

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.













**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 149:260057 CA
TITLE: GLP-1 (9-36) and its variants for inhibiting hyperglycemia or free fatty acid-induced reactive oxygen formation in mammalian cells and thereby preventing disease
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Yeshiva University, USA; Albert Einstein College of Medicine
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 582,116.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20080194483 | A1 | 20080814 | US 2008-8362 | 20080110 |
| WO 2005060986 | A1 | 20050707 | WO 2004-US40852 | 20041207 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20080015144 | A1 | 20080117 | US 2007-582116 | 20070626 |

PRIORITY APPLN. INFO.: US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626

REFERENCE 2

ACCESSION NUMBER: 143:91055 CA
TITLE: Glp-1 (9-36) methods and compositions
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Albert Einstein College of Medicine of Yeshiva University, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005060986 | A1 | 20050707 | WO 2004-US40852 | 20041207 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2550217 | A1 | 20050707 | CA 2004-2550217 | 20041207 |
| EP 1701731 | A1 | 20060920 | EP 2004-813201 | 20041207 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| US 20080015144 | A1 | 20080117 | US 2007-582116 | 20070626 |
| US 20080194483 | A1 | 20080814 | US 2008-8362 | 20080110 |

PRIORITY APPLN. INFO.: US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 4 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 856221-72-2 REGISTRY
CN L-Arginine, L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-N6-acetyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl- (CA INDEX NAME)
OTHER NAMES:
CN 6: PN: WO2005060986 SEQID: 6 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 29
NTE modified (modifications unspecified)

| type | location | | description |
|---|---|---|---|
| modification | Lys-18 | - | acetyl<Ac> |

PATENT ANNOTATIONS (PNTE):

| Sequence Source | Patent Reference |
|---|---|
| Not Given | WO2005060986 |
| | claimed SEQID |
| | 6 |

SEQ 1 EGTFTSDVSS YLEGQAAKEF IAWLVKGRR

HITS AT: 1-29

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**

MF C148 H227 N39 O46

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

DT.CA CAplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.





PAGE 1-B



PAGE 1-C





**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 149:260057 CA
TITLE: GLP-1 (9-36) and its variants for inhibiting hyperglycemia or free fatty acid-induced reactive oxygen formation in mammalian cells and thereby preventing disease
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Yeshiva University, USA; Albert Einstein College of Medicine
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 582,116.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20080194483 | A1 | 20080814 | US 2008-8362 | 20080110 |
| WO 2005060986 | A1 | 20050707 | WO 2004-US40852 | 20041207 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20080015144 | A1 | 20080117 | US 2007-582116 | 20070626 |

PRIORITY APPLN. INFO.: US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626

REFERENCE 2

ACCESSION NUMBER: 143:91055 CA
TITLE: Glp-1 (9-36) methods and compositions
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Albert Einstein College of Medicine of Yeshiva University, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005060986 | A1 | 20050707 | WO 2004-US40852 | 20041207 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2550217 | A1 | 20050707 | CA 2004-2550217 | 20041207 |
| EP 1701731 | A1 | 20060920 | EP 2004-813201 | 20041207 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| US 20080015144 | A1 | 20080117 | US 2007-582116 | 20070626 |
| US 20080194483 | A1 | 20080814 | US 2008-8362 | 20080110 |

PRIORITY APPLN. INFO.: US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 5 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 856221-69-7 REGISTRY
CN L-Arginine, L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl- (CA INDEX NAME)
OTHER NAMES:
CN 3: PN: WO2005060986 SEQID: 3 claimed protein
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 29

PATENT ANNOTATIONS (PNTE):

| Sequence Source | Patent Reference |
|---|---|
| Not Given | WO2005060986 claimed SEQID |

SEQ 1 EGTFTSDVSS YLEGQAAKEF IAWLVKGRR
========== ========== =========
HITS AT: 1-29

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
MF C146 H225 N39 O45
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PRP (Properties); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 149:260057 CA
TITLE: GLP-1 (9-36) and its variants for inhibiting hyperglycemia or free fatty acid-induced reactive oxygen formation in mammalian cells and thereby preventing disease

INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Yeshiva University, USA; Albert Einstein College of Medicine
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 582,116.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20080194483 | A1 | 20080814 | US 2008-8362 | 20080110 |
| WO 2005060986 | A1 | 20050707 | WO 2004-US40852 | 20041207 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20080015144 | A1 | 20080117 | US 2007-582116 | 20070626 |
| PRIORITY APPLN. INFO.: | | | US 2003-529247P | 20031212 |
| | | | WO 2004-US40852 | 20041207 |
| | | | US 2007-582116 | 20070626 |

REFERENCE 2

ACCESSION NUMBER: 143:91055 CA
TITLE: Glp-1 (9-36) methods and compositions
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Albert Einstein College of Medicine of Yeshiva University, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005060986 | A1 | 20050707 | WO 2004-US40852 | 20041207 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2550217 | A1 | 20050707 | CA 2004-2550217 | 20041207 |
| EP 1701731 | A1 | 20060920 | EP 2004-813201 | 20041207 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, | | | | |

IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

| | | | | |
|---|---|---|---|---|
| US 20080015144 | A1 | 20080117 | US 2007-582116 | 20070626 |
| US 20080194483 | A1 | 20080814 | US 2008-8362 | 20080110 |

PRIORITY APPLN. INFO.:
US 2003-529247P 20031212
WO 2004-US40852 20041207
US 2007-582116 20070626

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 6 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 683285-55-4 REGISTRY
CN L-Homoserine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 34
NTE

| type | location | | description |
|---|---|---|---|
| uncommon | Hse-34 | - | - |

SEQ 1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRRX
======== ========== ========== =
HITS AT: 3-31
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004037859 | A1 | 20040506 | WO 2003-JP13020 | 20031010 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

```
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2502118        A1   20040506       CA 2003-2502118  20031010
    AU 2003272970     A1   20040513       AU 2003-272970   20031010
    AU 2003272970     B2   20090528
    EP 1559724        A1   20050803       EP 2003-754074   20031010
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    CN 1703424        A    20051130       CN 2003-80101244 20031010
    CN 100354306      C    20071212
    US 20060194720    A1   20060831       US 2005-530125   20051027
    US 7291594        B2   20071106
PRIORITY APPLN. INFO.:                     JP 2002-299283   20021011
                                           WO 2003-JP13020  20031010
REFERENCE COUNT:         3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1   ANSWER 7 OF 14  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   683285-54-3  REGISTRY
CN   L-Arginine, L-histidyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-
     phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-
     L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-
     L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-
     tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl- (9CI)  (CA
     INDEX NAME)
FS   PROTEIN SEQUENCE
SQL  32

SEQ      1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR RR
           ======== ========== ========== =
HITS AT:   3-31
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, USPAT2, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); PRP
       (Properties); USES (Uses)
              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE  1

ACCESSION NUMBER:         140:380655  CA
TITLE:                    GLP-1 derivatives and transmucosal absorption
                          preparations thereof
INVENTOR(S):              Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki;
                          Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S):       Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 48 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2004037859     A1    20040506       WO 2003-JP13020  20031010
```

```
        W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
            GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
            OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2502118        A1   20040506       CA 2003-2502118  20031010
    AU 2003272970     A1   20040513       AU 2003-272970   20031010
    AU 2003272970     B2   20090528
    EP 1559724        A1   20050803       EP 2003-754074   20031010
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    CN 1703424        A    20051130       CN 2003-80101244 20031010
    CN 100354306      C    20071212
    US 20060194720    A1   20060831       US 2005-530125   20051027
    US 7291594        B2   20071106
PRIORITY APPLN. INFO.:                     JP 2002-299283   20021011
                                           WO 2003-JP13020  20031010
REFERENCE COUNT:         3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1   ANSWER 8 OF 14  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   683205-72-3  REGISTRY
CN   L-Arginine, L-histidyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-
     phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-
     L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-
     L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-
     tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl- (9CI)  (CA INDEX
     NAME)
FS   PROTEIN SEQUENCE; STEREOSEARCH
SQL  31

SEQ      1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR R
           ======== ========== ========== =
HITS AT:   3-31
MF   C155 H237 N43 O47
SR   CA
LC   STN Files:   CA, CAPLUS, USPAT2, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); PRP
       (Properties); USES (Uses)

Absolute stereochemistry.
```

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D





**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004037859 | A1 | 20040506 | WO 2003-JP13020 | 20031010 |
| W: | AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | |
| RW: | GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | |
| CA 2502118 | A1 | 20040506 | CA 2003-2502118 | 20031010 |
| AU 2003272970 | A1 | 20040513 | AU 2003-272970 | 20031010 |
| AU 2003272970 | B2 | 20090528 | | |
| EP 1559724 | A1 | 20050803 | EP 2003-754074 | 20031010 |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | |
| CN 1703424 | A | 20051130 | CN 2003-80101244 | 20031010 |
| CN 100354306 | C | 20071212 | | |

US 20060194720 A1 20060831 US 2005-530125 20051027
US 7291594 B2 20071106
PRIORITY APPLN. INFO.: JP 2002-299283 20021011
WO 2003-JP13020 20031010
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 9 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 682841-12-9 REGISTRY
CN L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 38

SEQ 1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRRRRRRR
======== ========== ========== =
HITS AT: 3-31
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004037859 | A1 | 20040506 | WO 2003-JP13020 | 20031010 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2502118 | A1 | 20040506 | CA 2003-2502118 | 20031010 |
| AU 2003272970 | A1 | 20040513 | AU 2003-272970 | 20031010 |
| AU 2003272970 | B2 | 20090528 | | |

```
     EP 1559724        A1   20050803       EP 2003-754074   20031010
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     CN 1703424        A    20051130       CN 2003-80101244 20031010
     CN 100354306      C    20071212
     US 20060194720    A1   20060831       US 2005-530125   20051027
     US 7291594        B2   20071106
PRIORITY APPLN. INFO.:                     JP 2002-299283   20021011
                                           WO 2003-JP13020  20031010
REFERENCE COUNT:         3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1   ANSWER 10 OF 14  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   682841-11-8  REGISTRY
CN   L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-
     phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-
     L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-
     L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-
     tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl-L-
     arginyl-L-arginyl-L-arginyl- (9CI)  (CA INDEX NAME)
FS   PROTEIN SEQUENCE
SQL  36

SEQ      1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRRRRR
           ======== ========== ========== =
HITS AT:   3-31
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, USPAT2, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); PRP
       (Properties); USES (Uses)
              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE  1

ACCESSION NUMBER:         140:380655  CA
TITLE:                    GLP-1 derivatives and transmucosal absorption
                          preparations thereof
INVENTOR(S):              Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki;
                          Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S):       Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 48 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2004037859     A1    20040506       WO 2003-JP13020  20031010
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
```

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| CA 2502118 | A1 | 20040506 | CA 2003-2502118 | 20031010 |
| AU 2003272970 | A1 | 20040513 | AU 2003-272970 | 20031010 |
| AU 2003272970 | B2 | 20090528 | | |
| EP 1559724 | A1 | 20050803 | EP 2003-754074 | 20031010 |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

| | | | | |
|---|---|---|---|---|
| CN 1703424 | A | 20051130 | CN 2003-80101244 | 20031010 |
| CN 100354306 | C | 20071212 | | |
| US 20060194720 | A1 | 20060831 | US 2005-530125 | 20051027 |
| US 7291594 | B2 | 20071106 | | |

PRIORITY APPLN. INFO.: JP 2002-299283 20021011
WO 2003-JP13020 20031010
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 11 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 682841-10-7 REGISTRY
CN L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 35

SEQ 1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRRRR
======== ========== ========== =
HITS AT: 3-31
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004037859 | A1 | 20040506 | WO 2003-JP13020 | 20031010 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,

```
            LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
            OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
            TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
            FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
            BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
    CA 2502118        A1   20040506       CA 2003-2502118  20031010
    AU 2003272970     A1   20040513       AU 2003-272970   20031010
    AU 2003272970     B2   20090528
    EP 1559724        A1   20050803       EP 2003-754074   20031010
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
    CN 1703424        A    20051130       CN 2003-80101244 20031010
    CN 100354306      C    20071212
    US 20060194720    A1   20060831       US 2005-530125   20051027
    US 7291594        B2   20071106
PRIORITY APPLN. INFO.:                    JP 2002-299283   20021011
                                          WO 2003-JP13020  20031010
REFERENCE COUNT:         3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                               RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1   ANSWER 12 OF 14  REGISTRY  COPYRIGHT 2010 ACS on STN
RN   682841-09-4  REGISTRY
CN   L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-
     phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-
     L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-
     L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-
     tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl-L-
     arginyl- (9CI)  (CA INDEX NAME)
FS   PROTEIN SEQUENCE
SQL  34

SEQ      1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRRR
             ======== ========== ========== =
HITS AT:   3-31

**RELATED SEQUENCES AVAILABLE WITH SEQLINK**
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   CA, CAPLUS, USPAT2, USPATFULL
DT.CA  CAplus document type:  Patent
RL.P   Roles from patents:  BIOL (Biological study); PREP (Preparation); PRP
       (Properties); USES (Uses)
              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE  1

ACCESSION NUMBER:         140:380655  CA
TITLE:                    GLP-1 derivatives and transmucosal absorption
                          preparations thereof
INVENTOR(S):              Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki;
                          Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S):       Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 48 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:
```

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004037859 | A1 | 20040506 | WO 2003-JP13020 | 20031010 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2502118 | A1 | 20040506 | CA 2003-2502118 | 20031010 |
| AU 2003272970 | A1 | 20040513 | AU 2003-272970 | 20031010 |
| AU 2003272970 | B2 | 20090528 | | |
| EP 1559724 | A1 | 20050803 | EP 2003-754074 | 20031010 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CN 1703424 | A | 20051130 | CN 2003-80101244 | 20031010 |
| CN 100354306 | C | 20071212 | | |
| US 20060194720 | A1 | 20060831 | US 2005-530125 | 20051027 |
| US 7291594 | B2 | 20071106 | | |
| PRIORITY APPLN. INFO.: | | | JP 2002-299283 | 20021011 |
| | | | WO 2003-JP13020 | 20031010 |

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 13 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 682841-08-3 REGISTRY
CN L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl-L-arginyl-(9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 33

SEQ 1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RRR
========= ========== ========== =

HITS AT: 3-31
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004037859 | A1 | 20040506 | WO 2003-JP13020 | 20031010 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2502118 | A1 | 20040506 | CA 2003-2502118 | 20031010 |
| AU 2003272970 | A1 | 20040513 | AU 2003-272970 | 20031010 |
| AU 2003272970 | B2 | 20090528 | | |
| EP 1559724 | A1 | 20050803 | EP 2003-754074 | 20031010 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CN 1703424 | A | 20051130 | CN 2003-80101244 | 20031010 |
| CN 100354306 | C | 20071212 | | |
| US 20060194720 | A1 | 20060831 | US 2005-530125 | 20051027 |
| US 7291594 | B2 | 20071106 | | |
| PRIORITY APPLN. INFO.: | | | JP 2002-299283 | 20021011 |
| | | | WO 2003-JP13020 | 20031010 |

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 14 OF 14 REGISTRY COPYRIGHT 2010 ACS on STN
RN 682841-07-2 REGISTRY
CN L-Arginine, L-histidyl-L-seryl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginyl-L-arginyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE
SQL 32

SEQ 1 HSEGTFTSDV SSYLEGQAAK EFIAWLVKGR RR
========= ========== ========== =
HITS AT: 3-31
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
DT.CA CAplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

ACCESSION NUMBER: 140:380655 CA
TITLE: GLP-1 derivatives and transmucosal absorption

```
                          preparations thereof
INVENTOR(S):              Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki;
                          Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S):       Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE:                   PCT Int. Appl., 48 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Japanese
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2004037859      A1   20040506       WO 2003-JP13020  20031010
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2502118         A1   20040506       CA 2003-2502118  20031010
     AU 2003272970      A1   20040513       AU 2003-272970   20031010
     AU 2003272970      B2   20090528
     EP 1559724         A1   20050803       EP 2003-754074   20031010
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     CN 1703424         A    20051130       CN 2003-80101244 20031010
     CN 100354306       C    20071212
     US 20060194720     A1   20060831       US 2005-530125   20051027
     US 7291594         B2   20071106
PRIORITY APPLN. INFO.:                      JP 2002-299283   20021011
                                            WO 2003-JP13020  20031010
REFERENCE COUNT:          3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> egtftsdvssylegqaakefiawlvkgr.r/sqsp
L2          190 EGTFTSDVSSYLEGQAAKEFIAWLVKGR.R/SQSP

=> egtftsdvssylegqaakefiawlvkgrr/sqep
              4 EGTFTSDVSSYLEGQAAKEFIAWLVKGRR/SQEP
         116602 SQL=29
L3            4 EGTFTSDVSSYLEGQAAKEFIAWLVKGRR/SQEP
                  (EGTFTSDVSSYLEGQAAKEFIAWLVKGRR/SQEP AND SQL=29)

=> egtftsdvssylegqaakefiawlvkgr.r/sqsp
L4          190 EGTFTSDVSSYLEGQAAKEFIAWLVKGR.R/SQSP

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             223.72     225.04

FILE 'CAPLUS' ENTERED AT 13:41:00 ON 07 MAR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 7 Mar 2010 VOL 152 ISS 11
FILE LAST UPDATED: 5 Mar 2010 (20100305/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> l2 and (diabetes or hyperglycemia)
            73 L2
        173773 DIABETES
         28634 HYPERGLYCEMIA
            35 HYPERGLYCEMIAS
         28653 HYPERGLYCEMIA
                  (HYPERGLYCEMIA OR HYPERGLYCEMIAS)
L5          28 L2 AND (DIABETES OR HYPERGLYCEMIA)

=> l2 and (diabetes or hyperglycemia or stroke)
            73 L2
        173773 DIABETES
         28634 HYPERGLYCEMIA
            35 HYPERGLYCEMIAS
         28653 HYPERGLYCEMIA
                  (HYPERGLYCEMIA OR HYPERGLYCEMIAS)
         46954 STROKE
          3029 STROKES
         48621 STROKE
                  (STROKE OR STROKES)
L6          28 L2 AND (DIABETES OR HYPERGLYCEMIA OR STROKE)

=> d ibib abs total l6

L6   ANSWER 1 OF 28  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2008:1180202  CAPLUS
DOCUMENT NUMBER:          149:418175
TITLE:                    Stable GLP-1 fusion peptides, their production and use
                          in treating diabetes and other disorders
INVENTOR(S):              Wallrapp, Christine; Thoenes, Eric; Geigle, Peter
PATENT ASSIGNEE(S):       Biocompatibles UK Ltd., UK
SOURCE:                   PCT Int. Appl., 86pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
```

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2008116648 | A2 | 20081002 | WO 2008-EP2414 | 20080327 |
| WO 2008116648 | A3 | 20081231 | | |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| EP 1975176 | A1 | 20081001 | EP 2007-6321 | 20070327 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| EP 2129687 | A2 | 20091209 | EP 2008-734805 | 20080327 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR | | | | |

| | | | |
|---|---|---|---|
| PRIORITY APPLN. INFO.: | EP 2007-6321 | A | 20070327 |
| | WO 2008-EP2414 | W | 20080327 |

OTHER SOURCE(S): MARPAT 149:418175

AB The present invention provides novel fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1 (7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of a homolog of native IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1 (7-35, 36 or 37)/IP2-homolog/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders. The present invention provides novel fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of a homolog of native IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2-homolog/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

L6 ANSWER 2 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

| | |
|---|---|
| ACCESSION NUMBER: | 2008:1179758 CAPLUS |
| DOCUMENT NUMBER: | 149:418174 |
| TITLE: | Stable GLP-1 fusion peptides, their production and use in treating diabetes and other disorders |
| INVENTOR(S): | Wallrapp, Christine; Thoenes, Eric; Geigle, Peter |
| PATENT ASSIGNEE(S): | Biocompatibles Uk Ltd., UK |

SOURCE: Eur. Pat. Appl., 83 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 1975176 | A1 | 20081001 | EP 2007-6321 | 20070327 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| WO 2008116648 | A2 | 20081002 | WO 2008-EP2414 | 20080327 |
| WO 2008116648 | A3 | 20081231 | | |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| EP 2129687 | A2 | 20091209 | EP 2008-734805 | 20080327 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR | | | | |

PRIORITY APPLN. INFO.: EP 2007-6321 A 20070327
WO 2008-EP2414 W 20080327

AB The present invention provides novel fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of a homolog of native IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2-homolog/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1157789 CAPLUS
DOCUMENT NUMBER: 149:395038
TITLE: Stable GLP-1 fusion peptides conjugated to synthetic or natural polymer(s), their production and use for treating diabetes and other diseases
INVENTOR(S): Wallrapp, Christine; Thoenes, Eric; Geigle, Peter
PATENT ASSIGNEE(S): Biocompatibles UK Ltd., UK
SOURCE: PCT Int. Appl., 122pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2008113601 | A1 | 20080925 | WO 2008-EP2278 | 20080320 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| EP 1972349 | A1 | 20080924 | EP 2007-5831 | 20070321 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| EP 2121032 | A1 | 20091125 | EP 2008-734709 | 20080320 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR | | | | |

PRIORITY APPLN. INFO.: EP 2007-5831 A 20070321
WO 2008-EP2278 W 20080320

OTHER SOURCE(S): MARPAT 149:395038

AB The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV conjugated to polymers, thereby forming conjugate mols. The fusion peptide of the conjugate mol. comprises as component (I) N-terminally a GLP-1 (7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. A synthetic polymer and/or a protein, e.g transferrin or albumin, is covalently or non-covalently bound to the fusion peptide to form the conjugate mol. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1 (7-35, 36 or 37)/IP2/GLP-1 (7-35, 36 or 37) or GLP-2 and a polymeric component, e.g. a natural or non-natural polymer. The fusion peptide may be produced in engineered cells or synthetically and is e.g. conjugated to the polymeric component by chemical synthesis. The conjugate mol. may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1151323 CAPLUS
DOCUMENT NUMBER: 149:395037
TITLE: Stable GLP-1 fusion peptides conjugated to synthetic or natural polymer(s), their production and use for treating diabetes and other diseases
INVENTOR(S): Geigle, Peter; Wallrapp, Christine; Thoenes, Eric
PATENT ASSIGNEE(S): Biocompatibles Uk Limited, UK
SOURCE: Eur. Pat. Appl., 120pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 1972349 | A1 | 20080924 | EP 2007-5831 | 20070321 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| WO 2008113601 | A1 | 20080925 | WO 2008-EP2278 | 20080320 |
| W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| EP 2121032 | A1 | 20091125 | EP 2008-734709 | 20080320 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR | | | | |

PRIORITY APPLN. INFO.: EP 2007-5831 A 20070321
WO 2008-EP2278 W 20080320

AB The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV, conjugated to polymers, thereby forming conjugate mols. The fusion peptide of the conjugate mol. comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. A synthetic polymer and/or a protein, e.g transferrin or albumin, is covalently or non-covalently bound to the fusion peptide to form the conjugate mol. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1(7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2 and a polymeric component, e.g. a natural or non-natural polymer. The fusion peptide may be produced in engineered cells or synthetically and is e.g. conjugated to the polymeric component by chemical synthesis. The conjugate mol. may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:981885 CAPLUS
DOCUMENT NUMBER: 149:260057
TITLE: GLP-1 (9-36) and its variants for inhibiting hyperglycemia or free fatty acid-induced reactive oxygen formation in mammalian cells and thereby preventing disease
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Yeshiva University, USA; Albert Einstein College of Medicine
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 582,116.
CODEN: USXXCO
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20080194483 | A1 | 20080814 | US 2008-8362 | 20080110 |
| WO 2005060986 | A1 | 20050707 | WO 2004-US40852 | 20041207 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20080015144 | A1 | 20080117 | US 2007-582116 | 20070626 |
| PRIORITY APPLN. INFO.: | | | US 2003-529247P P | 20031212 |
| | | | WO 2004-US40852 W | 20041207 |
| | | | US 2007-582116 A2 | 20070626 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods of inhibiting hyperglycemia-induced or free fatty acid-induced reactive oxygen formation in mammalian cells and mammals using the degradation product of glucagon-like peptide 1, GLP-1 (9-36) are provided. Various GLP-1 (9-36) variants are also provided. The cell is selected from the group consisting of a nerve cell, a renal mesangial cell, a pancreatic β cell, an adipocyte, a cardiac myocyte, an endothelial cell or a hepatocyte. In other embodiments, the invention is directed to methods of inhibiting the development of disease due to diabetes, impaired glucose tolerance, stress hyperglycemia , metabolic syndrome, insulin resistance, ischemia/reperfusion injury, endotoxin injury, non alc. steatohepatitis (NASH), alc. liver disease, and/or impaired glucose-stimulated insulin secretion in a mammal, or conditions resulting therefrom. The disease is an atherosclerotic, microvascular, or neurol. disease. More specifically the disease is selected from the group consisting of coronary disease, myocardial infarction, atherosclerotic peripheral vascular disease, cerebrovascular disease, stroke, retinopathy, renal disease, neuropathy, and cardiomyopathy.

L6 ANSWER 6 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:874968 CAPLUS
DOCUMENT NUMBER: 149:239352
TITLE: Fusion protein of human glucagon-like peptide-1 and application thereof
INVENTOR(S): Luo, Xiaoxing; Hui, Hongxiang; Ma, Xue
PATENT ASSIGNEE(S): Fourth Military Medical University, Pla, Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 21pp. CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| CN 101220088 | A | 20080716 | CN 2007-10018734 | 20070924 |
| PRIORITY APPLN. INFO.: | | | CN 2007-10018734 | 20070924 |

OTHER SOURCE(S): MARPAT 149:239352

AB The title fusion protein consists of n segments of peptide A (GLP-1(7-37) [SEQID No.1]) and n segments of peptide B (GLP-2(1-33) [SEQID No.2]). The inventive fusion protein is a prodrug that releases human glucagon-like peptide-1 (GLP-1) after enzymic degradation and thereby has pharmacol. action, and has high bioactivity and long half-time in vivo. The fusion protein can be used to treat or prevent disease or dysfunction associated with GLP-1, especially non-insulin-dependent diabetes mellitus. The invention has the advantages of low cost, simple operation, readily available raw material, and possible commercialized production

L6 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2008:586638 CAPLUS

DOCUMENT NUMBER: 148:554092

TITLE: Glp-1 derivative and use thereof

INVENTOR(S): Jomori, Takahito; Hayashi, Yuji; Makino, Mitsuhiro

PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan

SOURCE: PCT Int. Appl., 25 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2008056726 | A1 | 20080515 | WO 2007-JP71687 | 20071108 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| JP 2010043001 | A | 20100225 | JP 2006-304380 | 20061109 |

PRIORITY APPLN. INFO.: JP 2006-304380 A 20061109

AB [PROBLEMS] To provide a novel GLP-1 derivative having a largely improved capability of being absorbed through a mucous membrane. [MEANS FOR SOLVING PROBLEMS] Disclosed is a peptide which has (Lys)n-Arg [wherein n represents an integer of 4 to 8, and Arg is in the form of a carboxylic acid] added to the C-terminus of a peptide comprising an amino acid sequence corresponding to GLP-1 (7-35) or GLP-1 (7-36) or an amino acid sequence having the deletion, substitution and/or addition of one or several amino acid residues in the aforementioned amino acid sequence, having at least 85% homol. to the aforementioned amino acid sequence and having a GLP-1 activity. The amino acid residue at position-8 in the amino acid sequence for GLP-1 is preferably serine or glycine, and the integer "n" is preferably 5.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:1303151 CAPLUS

DOCUMENT NUMBER: 147:548045

TITLE: Spherical microcapsules comprising human mesenchymal stem cells expressing and secreting GLP-1 peptides and uses in treating diabetes

INVENTOR(S): Geigle, Peter; Wallrapp, Christine; Thoenes, Eric; Thuermer, Frank
PATENT ASSIGNEE(S): Biocompatibles UK Ltd., UK
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2007128443 | A2 | 20071115 | WO 2007-EP3775 | 20070427 |
| WO 2007128443 | A3 | 20080522 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA | | | | |
| EP 1854455 | A1 | 20071114 | EP 2006-9678 | 20060510 |
| EP 1854455 | B1 | 20091007 | | |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| AT 444741 | T | 20091015 | AT 2006-9678 | 20060510 |
| AU 2007247511 | A1 | 20071115 | AU 2007-247511 | 20070427 |
| CA 2649902 | A1 | 20071115 | CA 2007-2649902 | 20070427 |
| EP 2015736 | A2 | 20090121 | EP 2007-724702 | 20070427 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS | | | | |
| JP 2009536166 | T | 20091008 | JP 2009-508185 | 20070427 |
| IN 2008DN09530 | A | 20090619 | IN 2008-DN9530 | 20081114 |
| CN 101489539 | A | 20090722 | CN 2007-80026009 | 20090109 |

PRIORITY APPLN. INFO.: EP 2006-9678 A 20060510
WO 2007-EP3775 W 20070427

OTHER SOURCE(S): MARPAT 147:548045

AB The present invention provides spherical microcapsules comprising at least one surface coating and a core, wherein the at least one surface coating comprises cross-linked polymers, and wherein the core comprises cross-linked polymers and cells capable of expressing and secreting a GLP-1 peptide, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof. The present application is furthermore directed to methods for production of these spherical microcapsules and to the use of these microcapsules e.g. in the treatment of type 2 diabetes, weight disorders, neurodegenerative disorders or for the treatment of disorders and diseases or conditions associated to apoptosis. The cells contained in the core of the spherical microcapsule are selected from human mesenchymal stem cells, differentiated cells derived from human mesenchymal stem cells, including osteoblasts, chondrocytes, fat cells (adipocytes), or neuron-like cells including brain cells.

L6 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:355992 CAPLUS

DOCUMENT NUMBER: 146:351951
TITLE: Glp-1 (glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
INVENTOR(S): Geigle, Peter; Wallrapp, Christine; Thoenes, Eric
PATENT ASSIGNEE(S): Biocompatibles UK Limited, UK
SOURCE: Eur. Pat. Appl., 55pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 1767545 | A1 | 20070328 | EP 2005-20718 | 20050922 |
| EP 1767545 | B1 | 20091111 | | |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| EP 2045265 | A1 | 20090408 | EP 2008-21837 | 20050922 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU | | | | |
| AT 448247 | T | 20091115 | AT 2005-20718 | 20050922 |
| AU 2006299134 | A1 | 20070412 | AU 2006-299134 | 20060922 |
| CA 2619053 | A1 | 20070412 | CA 2006-2619053 | 20060922 |
| WO 2007039140 | A1 | 20070412 | WO 2006-EP9226 | 20060922 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| EP 1926748 | A1 | 20080604 | EP 2006-792228 | 20060922 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |
| JP 2009508505 | T | 20090305 | JP 2008-531616 | 20060922 |
| ZA 2008003488 | A | 20091028 | ZA 2008-3488 | 20060922 |
| IN 2008DN00642 | A | 20080711 | IN 2008-DN642 | 20080123 |
| MX 2008003591 | A | 20080410 | MX 2008-3591 | 20080313 |
| CN 101273058 | A | 20080924 | CN 2006-80035036 | 20080324 |
| KR 2008064840 | A | 20080709 | KR 2008-709543 | 20080421 |

PRIORITY APPLN. INFO.:
EP 2005-20718 A3 20050922
WO 2006-EP9226 W 20060922

AB The present invention provides fusion peptides having GLP-1 activity and enhanced stability in vivo, in particular resistancy to dipeptidyl peptidase IV. The fusion peptide comprises as component (I) N-terminally a GLP-1(7-35, 7-36 or 7-37) sequence and as component (II) C-terminally a peptide sequence of at least 9 amino acids or a functional fragment, variant or derivative thereof. Component (II) is preferably a full or partial version of IP2 (intervening peptide 2). A preferred embodiment comprises the sequence GLP-1 (7-35, 36 or 37)/IP2/GLP-1(7-35, 36 or 37) or GLP-2. The fusion peptide may be produced in engineered cells or synthetically and may be used for the preparation of a medicament for treating various diseases or disorders, e.g. diabetes type 1 or 2, apoptosis related diseases or neurodegenerative disorders.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:736536 CAPLUS
DOCUMENT NUMBER: 145:159868
TITLE: Stem cell and/or progenitor cells transplantation and methods for treating diabetes
INVENTOR(S): Harman, Mitchell
PATENT ASSIGNEE(S): Kronos Longevity Research Institute, USA
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2006079107 | A2 | 20060727 | WO 2006-US2626 | 20060123 |
| WO 2006079107 | A3 | 20070913 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-646476P P 20050122
AB The present invention relates to treatments for diabetes, particularly type 1 diabetes of human. The invention relates to methods and compns. for administering donor cells (e.g., stem cells and/or progenitor cells) to a type 1 diabetic subject and differentiating the stem cells in vivo to produce insulin secreting cells. Certain aspects of the invention relate to kits including one or more donor cells and/or pancreatic differentiation factors and/or immunosuppressant agents.

L6 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:209376 CAPLUS
DOCUMENT NUMBER: 144:247750
TITLE: Induction of hormone gene expression and insulin secretion in pancreatic β cells by islet cell autoantigen ICA512
INVENTOR(S): Trajkovski, Mirko; Mziaut, Hassan; Solimena, Michele
PATENT ASSIGNEE(S): Technische Universitaet Dresden Medizinische Fakultaet Carl Gustav Carus, Germany
SOURCE: Eur. Pat. Appl., 63 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

EP 1632245 A1 20060308 EP 2004-20912 20040902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
CA 2578940 A1 20060323 CA 2005-2578940 20050902
WO 2006029728 A1 20060323 WO 2005-EP9473 20050902
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
EP 1784207 A1 20070516 EP 2005-791045 20050902
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU
JP 2008511297 T 20080417 JP 2007-528787 20050902
US 20090131309 A1 20090521 US 2008-574568 20080201
PRIORITY APPLN. INFO.: EP 2004-20912 A 20040902
WO 2005-EP9473 W 20050902
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Islet cell autoantigen ICA512 and C-terminal fragments derived from it are found to be capable of inducing insulin secretion and peptide hormone biosynthesis in islet cells or neurons. The protein may be cleaved with μ calpain to generate a C-terminal fragment of that is targeted to the nucleus. It is preferred in accordance with the invention that said endocrine cells are β-cells and that said peptide hormone is insulin.
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1311452 CAPLUS
DOCUMENT NUMBER: 144:45723
TITLE: Splice variants of members of the pancreatic peptide family for use in therapeutic regulation of metabolism
INVENTOR(S): Shemesh, Ronen; Kliger, Yossef; Neville, Lewis F.; Bernstein, Jeanne; Eshel, Dani
PATENT ASSIGNEE(S): Compugen Ltd., Israel
SOURCE: PCT Int. Appl., 180 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005118786 | A2 | 20051215 | WO 2005-IL588 | 20050602 |
| WO 2005118786 | A3 | 20080117 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,

ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA

US 20060052301 A1 20060309 US 2005-145463 20050602
PRIORITY APPLN. INFO.: US 2004-576414P P 20040603
US 2005-672987P P 20050420
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Splice variants of amylin and other members of the pancreatic polypeptide family, namely peptide YY, peptide Y, and neuropeptide Y, are identified. These variants of these proteins may be useful useful in the treatment of metabolic disorders (no data.). Levels of these proteins may be increased by direct administration, or by delivery of a suitable expression vector carrying the corresponding coding sequence. Alternatively, levels may be lowered by administration of an inhibitor such as an antibody. Administration of a peptide YY variant was effective in slowing weight gain in genetically obese mice.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L6 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:961959 CAPLUS
DOCUMENT NUMBER: 143:261378
TITLE: A method for the recombinant production of proteins useful in treatment of obesity and diabetes from the milk of transgenic animals, and therapeutic applications
INVENTOR(S): Olsen, Byron
PATENT ASSIGNEE(S): Gtc Biotherapeutics, Inc., USA; Olsen, Byron
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005079525 | A2 | 20050901 | WO 2005-US5406 | 20050218 |
| WO 2005079525 | A3 | 20061228 | | |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, SM, US
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20060182744 A1 20060817 US 2005-58458 20050215
PRIORITY APPLN. INFO.: US 2004-545790P P 20040219
US 2005-58458 A1 20050215
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The current invention provides a method for the production of therapeutic proteins useful in the treatment of obesity and related conditions through the use of transgenic animals, particularly, from the milk or other bodily fluid of the transgenic animals. In particular the current invention provides for the production of Leptin and other anti-aging mols. in the milk

of transgenic mammals, particularly non-human placental mammals and provides for the use of such transgenic proteins in therapeutic applications or disease conditions. A nuclear transfer procedure can be conducted to generate a mass of transgenic cells useful for research, serial cloning, or other in vitro use. Another aspect of this invention is directed to a method for treating Type II diabetes mellitus comprising administering to a mammal a therapeutically effective amount of a transgenic protein of interest, a prodrug thereof, or a pharmaceutically acceptable salt thereof in addition to a modified lower dosing of insulin via pump means.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L6 ANSWER 14 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:904226 CAPLUS
DOCUMENT NUMBER: 143:243023
TITLE: Vector constructs comprising mammary tissue-specific promoter for production of transgenic proteins useful in the treatment of obesity and diabetes
INVENTOR(S): Olsen, Byron V.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 46 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| US 20050186608 | A1 | 20050825 | US 2005-60291 | | 20050217 |
| PRIORITY APPLN. INFO.: | | | US 2004-545790P | P | 20040219 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Transgenic proteins therapeutically useful in the treatment of obesity and related conditions can be produced in and purified from the milk of transgenic animals. Transgene DNA constructs are described which are operatively linked to a mammary tissue-specific promoter (e.g., the β-casein promoter) which enable the transgenic protein product to be expressed in the milk of a transgenic non-human mammal. The peptides are made as transgenic proteins with a suitable transgenic partner such as human recombinant protein of interest.

L6 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:588685 CAPLUS
DOCUMENT NUMBER: 143:91055
TITLE: Glp-1 (9-36) methods and compositions
INVENTOR(S): Brownlee, Michael A.
PATENT ASSIGNEE(S): Albert Einstein College of Medicine of Yeshiva University, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005060986 | A1 | 20050707 | WO 2004-US40852 | 20041207 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, | | | | |

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| CA 2550217 | A1 | 20050707 | CA 2004-2550217 | 20041207 |
| EP 1701731 | A1 | 20060920 | EP 2004-813201 | 20041207 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS | | | | |
| US 20080015144 | A1 | 20080117 | US 2007-582116 | 20070626 |
| US 20080194483 | A1 | 20080814 | US 2008-8362 | 20080110 |
| PRIORITY APPLN. INFO.: | | | US 2003-529247P | P 20031212 |
| | | | WO 2004-US40852 | W 20041207 |
| | | | US 2007-582116 | A2 20070626 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Methods of inhibiting hyperglycemia-induced or free fatty acid-induced reactive oxygen formation in mammalian cells and mammals using the degradation product of glucagon-like peptide 1, GLP-1 (9-36) are provided. Various GLP-1 (9-36) compns. are also provided.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:485594 CAPLUS

DOCUMENT NUMBER: 143:32219

TITLE: Analogs of glucagon-like peptide-1 for treatment of metabolic, neurological, and aging-associated disorders

INVENTOR(S): Dong, Zheng Xin

PATENT ASSIGNEE(S): Societe de Conseils De Recherches e d'Applications Scientifiques, S.A.S., Fr.

SOURCE: U.S., 174 pp., Cont.-in-part of U.S. Ser. No. 206,601, abandoned.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 6903186 | B1 | 20050607 | US 2001-857636 | 20011102 |
| WO 2000034331 | A2 | 20000615 | WO 1999-EP9660 | 19991207 |
| WO 2000034331 | A3 | 20001116 | | |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1359159 | A2 | 20031105 | EP 2003-76490 | 19991207 |
| EP 1359159 | A3 | 20040721 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY | | | | |
| ZA 200304047 | A | 20040203 | ZA 2003-4047 | 19991207 |

| | | | | | |
|---|---|---|---|---|---|
| RU 2288232 | C2 | 20061127 | RU 2003-112447 | | 19991207 |
| CN 1935839 | A | 20070328 | CN 2006-10159555 | | 19991207 |
| ZA 2001004478 | A | 20031201 | ZA 2001-4478 | | 20010531 |
| AU 2003202533 | A1 | 20030612 | AU 2003-202533 | | 20030327 |
| AU 2003202533 | B2 | 20050421 | | | |
| US 7268213 | B2 | 20070911 | US 2003-629261 | | 20030728 |
| US 20040018981 | A1 | 20040129 | | | |
| JP 2004131473 | A | 20040430 | JP 2003-283316 | | 20030731 |
| JP 3934092 | B2 | 20070620 | | | |
| JP 2005132845 | A | 20050526 | JP 2004-363831 | | 20041216 |
| BR 2005000392 | A | 20060926 | BR 2005-392 | | 20050215 |
| US 20050233969 | A1 | 20051020 | US 2005-145782 | | 20050606 |
| US 7235628 | B2 | 20070626 | | | |
| JP 2006151988 | A | 20060615 | JP 2005-374822 | | 20051227 |
| JP 4386887 | B2 | 20091216 | | | |
| US 20080108566 | A1 | 20080508 | US 2007-781096 | | 20070720 |
| JP 2008001710 | A | 20080110 | JP 2007-191581 | | 20070724 |
| US 20090197802 | A1 | 20090806 | US 2007-929013 | | 20071030 |
| PRIORITY APPLN. INFO.: | | | US 1998-111255P | P | 19981207 |
| | | | US 1998-206601 | B2 | 19981207 |
| | | | WO 1999-EP9660 | W | 19991207 |
| | | | AU 2000-19736 | A3 | 19991207 |
| | | | CN 1999-814187 | A3 | 19991207 |
| | | | EP 1999-963437 | A3 | 19991207 |
| | | | JP 2000-586773 | A3 | 19991207 |
| | | | RU 2001-118855 | A | 19991207 |
| | | | US 2001-857636 | A2 | 20011102 |
| | | | US 2003-629261 | A1 | 20030728 |
| | | | JP 2003-283316 | A3 | 20030731 |
| | | | JP 2005-374822 | A3 | 20051227 |
| | | | US 2007-781096 | A1 | 20070720 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 143:32219

AB Peptide analogs of glucagon-like peptide-1 (GLP-1) with increased plasma half-lives that can be used to treat metabolic, neurol., and disease associated with aging are described. GLP-1 is metabolically unstable, with a plasma half-life of only 1-2 min in vivo, there is therefore a need for GLP-1 analogs that are more active or are more metabolically stable than native GLP-1. Specifically, analogs of human GLP-1(7-36)amide that are agonists for the GLP-1 receptor are described for the treatment of mammalian disorders such as type 1 and type 2 diabetes. The invention provides 773 different analogs, a preferred analog comprising (Ser8,Aib35)hGLP-1(7-36)NH2.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:347172 CAPLUS
DOCUMENT NUMBER: 142:405586
TITLE: Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
INVENTOR(S): Shemesh, Ronen; Kliger, Yossef; Neville, Lewis F.; Bernstein, Jeanne; Cohen-Dayag, Anat; Eshel, Dani
PATENT ASSIGNEE(S): Compugen Ltd., Israel
SOURCE: PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005035761 | A1 | 20050421 | WO 2004-IL952 | 20041017 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-685712 A 20031016
US 2004-576414P P 20040603

AB The present invention relates to alternative splice variants of preproglucagon, glucagon-like peptide-1 (GLP-1) and oxyntomodulin (OXM), vectors and compns. comprising same, and methods of use thereof. This invention provides peptides, nucleic acid sequences which encode same, analogs and derivs. thereof, antibodies, which specifically recognize the variant sequences, compns. comprising same and methods of use thereof. These splice isoforms showed activities in diabetes, nervous system disorders, post surgery treatment, obesity and cardiovascular disease.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:232600 CAPLUS
DOCUMENT NUMBER: 142:311675
TITLE: Use of polypyrimidine tract binding protein in insulin secretory granule biogenesis, drug screening, and therapy
INVENTOR(S): Solimena, Michele; Knoch, Klaus-Peter
PATENT ASSIGNEE(S): Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V., Germany; Technische Universitaet Dresden Medizinische Fakultaet Carl Gustav Carus
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005023231 | A1 | 20050317 | WO 2004-EP10167 | 20040910 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2003-20640 A 20030910
EP 2004-3429 A 20040216

AB The present invention relates to a method for stimulating production of secretory granules in peptide hormone-secreting endocrine cells or neurons comprising the step of promoting the presence of polypyrimidine tract binding protein (pPTB) or a biol. active fragment or derivative thereof in the cytoplasm of said cells or neurons. Preferably, the method alternatively or further comprises promoting the activity of pPTB or said biol. active fragment or derivative thereof in the cytoplasm of said cells or neurons. It is also preferred that said promotion comprises the promotion of the nucleocytoplasmic transport of pPTB. In another aspect, the invention relates to a method of screening for an agent capable of stimulating production of secretory granules in peptide hormone-secreting endocrine cells or neurons comprising the steps of (a) contacting a cell capable of forming secretory granules and expressing polypyrimidine tract binding protein (pPTB) or a biol. active fragment or derivative thereof with one or more compds.; and (b) assessing whether said one or more compds. promote the presence or activity of said polypyrimidine tract binding protein (pPTB) or said biol. active fragment or derivative thereof in the cytoplasm of said cell. The invention comprises further methods of screening for an agent useful as a cure for diabetes, sleeping disorders, or depression as well as various medical uses of an agent capable of the promotion/reduction of the presence or activity of polypyrimidine tract binding protein (pPTB) or of a biol. active fragment or derivative thereof. In alternative embodiments, the invention also includes the reduction or down regulation of pPTB or said biol. active fragment or derivative thereof. In examples of the invention, glucose stimulated activation of pPTB, promoted the stability of ICA512, a receptor tyrosine phosphatase-like protein associated with insulin secretory granules, and upregulated ICA512 mRNA. Glucose stimulation promoted the binding of cytosolic pPTB to the 3'-UTR of ICA512 mRNA and pPTB binding activity correlated with ICA512 mRNA stability. Downregulation of pPTB by RNA interference decreased expression of secretory granule components with pPTB-binding sites in the 3'-untranslated region of their mRNAs. PPTB was phosphorylated on serine residue 16 in a cAMP and protein kinase A-dependent process that regulated translocation of pPTB between the nucleus and the cytoplasm.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:732210 CAPLUS
DOCUMENT NUMBER: 141:237101
TITLE: Methods to induce the conversion of intestinal cells into insulin-producing cells with preproglucagon fragments
INVENTOR(S): Taniguchi, Hideki; Suzuki, Atsushi; Eto, Yuzuru
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan
SOURCE: Eur. Pat. Appl., 23 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 1454629 | A2 | 20040908 | EP 2004-5144 | 20040304 |
| EP 1454629 | A3 | 20041201 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK | | | | |
| WO 2004078195 | A1 | 20040916 | WO 2004-JP2001 | 20040220 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, | | | | |

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| US 20040214321 | A1 | 20041028 | US 2004-793677 | 20040305 |
| US 7423019 | B2 | 20080909 | | |

PRIORITY APPLN. INFO.: JP 2003-61836 A 20030307
JP 2003-358111 A 20031017

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB A partial peptide of a preproglucagon peptide comprising at least the amino acid sequence at positions 92-97 of a preproglucagon peptide is used as an effective ingredient of an antidiabetic drug. Methods for the application of this patent to insulin bioindustrial manufacture are also provided.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:718564 CAPLUS
DOCUMENT NUMBER: 141:248703
TITLE: Analogs of glucagon-like peptide-1 for treatment of mammalian disorders
INVENTOR(S): Dong, Zheng Xin
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques S.C.R.A.S., Fr.
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004074315 | A2 | 20040902 | WO 2004-US4421 | 20040217 |
| WO 2004074315 | A3 | 20041125 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2513307 | A1 | 20040902 | CA 2004-2513307 | 20040217 |
| EP 1594529 | A2 | 20051116 | EP 2004-711811 | 20040217 |
| EP 1594529 | B1 | 20100120 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CN 1750842 | A | 20060322 | CN 2004-80004658 | 20040217 |
| JP 2007524579 | T | 20070830 | JP 2006-503594 | 20040217 |
| EP 2067483 | A1 | 20090610 | EP 2009-156363 | 20040217 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR, AL, LT, LV, MK | | | | |
| AT 455555 | T | 20100215 | AT 2004-711811 | 20040217 |
| TW 283684 | B | 20070711 | TW 2004-93104154 | 20040219 |
| US 20060217300 | A1 | 20060928 | US 2005-546303 | 20050819 |

PRIORITY APPLN. INFO.: US 2003-449203P P 20030219
EP 2004-711811 A3 20040217
WO 2004-US4421 W 20040217
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 141:248703
AB The present invention is directed to peptide analogs of glucagon-like peptide-1 (GLP-1), and more specifically human GLP-1(7-36)amide, and to methods of using such analogs to have agonist effect on the GLP-1 receptor in the treatment of mammalian disorders such as type 1 and type 2 diabetes. Since GLP-1 is metabolically unstable, having a plasma half-life of only 1-2 min in vivo, there is a need for GLP-1 analogs that are more active or are more metabolically stable than native GLP-1. The invention provides 773 different analogs, a preferred analog comprising (Ser8,Aib35)hGLP-1(7-36)NH2.
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:648538 CAPLUS
DOCUMENT NUMBER: 141:191072
TITLE: Preparation and use of chemically-modified metabolites of regulatory peptides
INVENTOR(S): Peri, Krishna; Habi, Abdelkrim; Gravel, Denis
PATENT ASSIGNEE(S): Theratechnologies Inc., Can.
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004067548 | A2 | 20040812 | WO 2004-CA131 | 20040130 |
| WO 2004067548 | A3 | 20041209 | | |
| WO 2004067548 | B1 | 20050217 | | |
| W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI | | | | |
| US 20050059605 | A1 | 20050317 | US 2004-768974 | 20040130 |

PRIORITY APPLN. INFO.: US 2003-443860P P 20030131
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 141:191072
AB The invention relates to peptides B-A-CO-P or their pharmaceutically-acceptable salts, where P is a dipeptidyl-peptidase (DPPIV) peptide metabolite of regulatory peptides obtained by cleavage of the two N-terminal amino acids, A is (hetero)alk(en)(yn)ylene or Ph and B is (un)substituted (hetero)aryl or cycloalkyl. More specifically, the invention relates to conferring biol. activity to metabolites of regulatory peptides by the covalent coupling of small mols. Thus, 3-(4-methoxyphenethylamino)-3-oxopropanoyl-GLP-1 (9-36) was prepared by solid-phase peptide chemical and N-acylation and shown to produce a more significant hypoglycemic response in mice compared to native GLP-1.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:370962 CAPLUS
DOCUMENT NUMBER: 140:380655
TITLE: GLP-1 derivatives and transmucosal absorption preparations thereof
INVENTOR(S): Hayashi, Yuji; Makino, Mitsuhiro; Kouzaki, Toshiyuki; Takeda, Motohiro; Jomori, Takahito
PATENT ASSIGNEE(S): Sanwa Kagaku Kenkyusho Co., Ltd., Japan
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004037859 | A1 | 20040506 | WO 2003-JP13020 | 20031010 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2502118 | A1 | 20040506 | CA 2003-2502118 | 20031010 |
| AU 2003272970 | A1 | 20040513 | AU 2003-272970 | 20031010 |
| AU 2003272970 | B2 | 20090528 | | |
| EP 1559724 | A1 | 20050803 | EP 2003-754074 | 20031010 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| CN 1703424 | A | 20051130 | CN 2003-80101244 | 20031010 |
| CN 100354306 | C | 20071212 | | |
| US 20060194720 | A1 | 20060831 | US 2005-530125 | 20051027 |
| US 7291594 | B2 | 20071106 | | |

PRIORITY APPLN. INFO.: JP 2002-299283 A 20021011
WO 2003-JP13020 W 20031010
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB Disclosed is a GLP-1 derivative comprising a peptide having an amino acid sequence derived from the amino acid sequence of GLP-1 (7-35) by deletion, substitution and/or addition of one to several amino acids and having a GLP-1 activity to the C-terminus of which a sequence Waa-(Xaa)n-Yaa (wherein Waa represents Arg or Lys; Xaa represents Arg or Lys; n is an integer of from 0 to 14; and Yaa represents Arg, Arg-NH2, Lys, Lys-NH2 or Hse) is added. This derivative has a high transmucosal absorbability. Moreover, tolerance to dipeptidyl peptidase IV can be imparted to the derivative by substituting the 8-position of the GLP-1 amino acid sequence into Ser, while tolerance to trypsin can be imparted thereto by substituting the 26-position into Gln and the 34-position into Asn. The transmucosal absorbability of the above GLP-1 derivative can be further elevated by formulating into a preparation with the
use of a charge-controller fat emulsifier having a surface charge controlled to the neg. level.
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:41516 CAPLUS
DOCUMENT NUMBER: 140:105831
TITLE: Pharmaceutical compositions and uses of GLP-1 mimetics for the treatment of diabetes
INVENTOR(S): Steiness, Eva
PATENT ASSIGNEE(S): Zealand Pharma A/S, Den.
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2004005342 | A1 | 20040115 | WO 2003-DK463 | 20030702 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2490564 | A1 | 20040115 | CA 2003-2490564 | 20030702 |
| AU 2003243929 | A1 | 20040123 | AU 2003-243929 | 20030702 |
| AU 2003243929 | B2 | 20090604 | | |
| EP 1525219 | A1 | 20050427 | EP 2003-762471 | 20030702 |
| EP 1525219 | B1 | 20090527 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| JP 2006515267 | T | 20060525 | JP 2004-518465 | 20030702 |
| EP 2028192 | A1 | 20090225 | EP 2008-16668 | 20030702 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR | | | | |
| AT 432289 | T | 20090615 | AT 2003-762471 | 20030702 |
| ES 2327328 | T3 | 20091028 | ES 2003-762471 | 20030702 |
| MX 2004012497 | A | 20050714 | MX 2004-12497 | 20041210 |
| US 20060057137 | A1 | 20060316 | US 2005-517563 | 20050708 |
| HK 1075456 | A1 | 20091231 | HK 2005-106202 | 20050722 |
| US 20090088369 | A1 | 20090402 | US 2008-277148 | 20081124 |
| AU 2009202390 | A1 | 20090709 | AU 2009-202390 | 20090615 |

| PRIORITY APPLN. INFO.: | | |
|---|---|---|
| US 2002-393917P | P | 20020704 |
| US 2003-465613P | P | 20030424 |
| AU 2003-243929 | A3 | 20030702 |
| EP 2003-762471 | A3 | 20030702 |
| WO 2003-DK463 | W | 20030702 |
| US 2005-517563 | A1 | 20050708 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to use of GLP-1 or a related mol. having GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a 'drug holiday'. Practice of the invention achieves effective therapy without continuous drug exposure and without continuous presence of therapeutic levels of the drug. The invention also discloses a method of treating diabetes and related disorders in a mammal by administering glucagon like peptide (GLP-1) or a related mol. having GLP-1 like effect and thereby providing a therapeutically effective amount of endogenous insulin.

OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD

(3 CITINGS)
REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:571103 CAPLUS
DOCUMENT NUMBER: 139:122690
TITLE: Albumin fusion proteins for prolonged shelf-life of therapeutic proteins
INVENTOR(S): Ballance, David James; Turner, Andrew John; Rosen, Craig A.; Haseltine, William A.
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; Delta Biotechnology Limited; Principia Pharmaceutical Corporation
SOURCE: PCT Int. Appl., 598 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003060071 | A2 | 20030724 | WO 2002-US40891 | 20021223 |
| WO 2003060071 | A3 | 20040226 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2471363 | A1 | 20030724 | CA 2002-2471363 | 20021223 |
| AU 2002364586 | A1 | 20030730 | AU 2002-364586 | 20021223 |
| EP 1463751 | A2 | 20041006 | EP 2002-799966 | 20021223 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| JP 2005514060 | T | 20050519 | JP 2003-560158 | 20021223 |
| EP 1997829 | A1 | 20081203 | EP 2008-75724 | 20021223 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SI, SK, TR | | | | |
| US 20050186664 | A1 | 20050825 | US 2004-775204 | 20040211 |
| US 7141547 | B2 | 20061128 | | |
| JP 2006176514 | A | 20060706 | JP 2005-365640 | 20051219 |
| US 20060194735 | A1 | 20060831 | US 2006-429276 | 20060508 |
| US 7592010 | B2 | 20090922 | | |
| US 20060276396 | A1 | 20061207 | US 2006-429373 | 20060508 |
| US 7238667 | B2 | 20070703 | | |
| US 20080213886 | A1 | 20080904 | US 2006-429374 | 20060508 |
| US 20080004206 | A1 | 20080103 | US 2006-495624 | 20060731 |
| US 20070244047 | A1 | 20071018 | US 2007-714841 | 20070307 |
| US 20070259815 | A1 | 20071108 | US 2007-783419 | 20070409 |
| US 20080146503 | A1 | 20080619 | US 2007-772643 | 20070702 |
| US 20080153751 | A1 | 20080626 | US 2007-929828 | 20071030 |
| US 20080161243 | A1 | 20080703 | US 2007-929714 | 20071030 |
| US 20080167238 | A1 | 20080710 | US 2007-929912 | 20071030 |
| US 20080167239 | A1 | 20080710 | US 2007-929939 | 20071030 |
| US 20080167240 | A1 | 20080710 | US 2007-929953 | 20071030 |
| US 20090093402 | A1 | 20090409 | US 2007-929702 | 20071030 |
| US 20090099073 | A1 | 20090416 | US 2007-929946 | 20071030 |

| | | | | | |
|---|---|---|---|---|---|
| US 20080194481 | A1 | 20080814 | US 2007-932823 | | 20071031 |
| JP 2009213477 | A | 20090924 | JP 2009-109615 | | 20090428 |
| PRIORITY APPLN. INFO.: | | | US 2001-341811P | P | 20011221 |
| | | | US 2002-350358P | P | 20020124 |
| | | | US 2002-351360P | P | 20020128 |
| | | | US 2002-359370P | P | 20020226 |
| | | | US 2002-360000P | P | 20020228 |
| | | | US 2002-367500P | P | 20020327 |
| | | | US 2002-370227P | P | 20020408 |
| | | | US 2002-378950P | P | 20020510 |
| | | | US 2002-382617P | P | 20020524 |
| | | | US 2002-383123P | P | 20020528 |
| | | | US 2002-385708P | P | 20020605 |
| | | | US 2002-394625P | P | 20020710 |
| | | | US 2002-398008P | P | 20020724 |
| | | | US 2002-402131P | P | 20020809 |
| | | | US 2002-402708P | P | 20020813 |
| | | | US 2002-411355P | P | 20020918 |
| | | | US 2002-411426P | P | 20020918 |
| | | | US 2002-414984P | P | 20021002 |
| | | | US 2002-417611P | P | 20021011 |
| | | | US 2002-420246P | P | 20021023 |
| | | | US 2002-423623P | P | 20021105 |
| | | | EP 2002-799966 | A3 | 20021223 |
| | | | JP 2003-560158 | A3 | 20021223 |
| | | | WO 2002-US40891 | W | 20021223 |
| | | | US 2003-441305P | P | 20030122 |
| | | | US 2003-453201P | P | 20030311 |
| | | | US 2003-467222P | P | 20030502 |
| | | | US 2003-472816P | P | 20030523 |
| | | | US 2003-476267P | P | 20030606 |
| | | | US 2003-505172P | P | 20030924 |
| | | | US 2003-506746P | P | 20030930 |
| | | | WO 2004-US1369 | A1 | 20040120 |
| | | | US 2004-542274P | P | 20040209 |
| | | | US 2004-775204 | A1 | 20040211 |
| | | | US 2004-549901P | P | 20040305 |
| | | | US 2004-556906P | P | 20040329 |
| | | | US 2004-636603P | P | 20041217 |
| | | | WO 2005-US4041 | A2 | 20050209 |
| | | | US 2005-175690 | A2 | 20050707 |
| | | | US 2005-707521P | P | 20050812 |
| | | | US 2005-712386P | P | 20050831 |
| | | | US 2005-732724P | P | 20051103 |
| | | | US 2006-776914P | P | 20060228 |
| | | | US 2006-781361P | P | 20060313 |
| | | | US 2006-429276 | A2 | 20060508 |
| | | | US 2006-429373 | A3 | 20060508 |
| | | | US 2006-810182P | P | 20060602 |
| | | | US 2006-813682P | P | 20060615 |
| | | | US 2006-495624 | A2 | 20060731 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention encompasses albumin fusion proteins. Many therapeutic proteins in their native state or when recombinantly produced are typically labile mols. exhibiting short shelf-lives, particularly when formulated in aqueous solns.; fusions of the therapeutic protein with human serum albumin have a longer serum half-life and/or stabilized activity in solution (or in a pharmaceutical composition) in vitro and/or in vivo than the corresponding unfused therapeutic mols. Thus, albumin fusion proteins are provided comprising granulocyte colony-stimulating factor, interleukin 2, parathormone, erythropoietin, interferon β, interferon α2, interferon A/D hybrid, a single-chain insulin analog, growth hormone, and

(7-36)GLP-1. Nucleic acid mols. encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Addnl. the present invention encompasses pharmaceutical compns. comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L6 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:571004 CAPLUS
DOCUMENT NUMBER: 139:122689
TITLE: Albumin fusion proteins for prolonged shelf-life of therapeutic proteins
INVENTOR(S): Rosen, Craig A.; Haseltine, William A.
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
SOURCE: PCT Int. Appl., 1086 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2003059934 | A2 | 20030724 | WO 2002-US40892 | | 20021223 |
| WO 2003059934 | A3 | 20040226 | | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| CA 2484556 | A1 | 20030724 | CA 2002-2484556 | | 20021223 |
| AU 2002364587 | A1 | 20030730 | AU 2002-364587 | | 20021223 |
| EP 1463752 | A2 | 20041006 | EP 2002-799967 | | 20021223 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | | |
| EP 1997829 | A1 | 20081203 | EP 2008-75724 | | 20021223 |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SI, SK, TR | | | | | |
| US 20050054570 | A1 | 20050310 | US 2004-775180 | | 20040211 |
| US 7189690 | B2 | 20070313 | | | |
| JP 2006176514 | A | 20060706 | JP 2005-365640 | | 20051219 |
| US 20060286635 | A1 | 20061221 | US 2006-393893 | | 20060331 |
| US 7238660 | B2 | 20070703 | | | |
| US 20080293629 | A1 | 20081127 | US 2007-772591 | | 20070702 |
| JP 2009213477 | A | 20090924 | JP 2009-109615 | | 20090428 |
| PRIORITY APPLN. INFO.: | | | US 2001-341811P | P | 20011221 |
| | | | US 2002-350358P | P | 20020124 |
| | | | US 2002-359370P | P | 20020226 |
| | | | US 2002-360000P | P | 20020228 |
| | | | US 2002-367500P | P | 20020327 |
| | | | US 2002-370227P | P | 20020408 |
| | | | US 2002-378950P | P | 20020510 |

| | | |
|---|---|---|
| US 2002-398008P | P | 20020724 |
| US 2002-402131P | P | 20020809 |
| US 2002-402708P | P | 20020813 |
| US 2002-411355P | P | 20020918 |
| US 2002-414984P | P | 20021002 |
| US 2002-417611P | P | 20021011 |
| US 2002-420246P | P | 20021023 |
| US 2002-423623P | P | 20021105 |
| US 2002-351360P | P | 20020128 |
| US 2002-382617P | P | 20020524 |
| US 2002-383123P | P | 20020528 |
| US 2002-385708P | P | 20020605 |
| US 2002-394625P | P | 20020710 |
| US 2002-411426P | P | 20020918 |
| EP 2002-799966 | A3 | 20021223 |
| JP 2003-560158 | A3 | 20021223 |
| WO 2002-US40892 | W | 20021223 |
| US 2004-775180 | A1 | 20040211 |
| US 2006-393893 | A1 | 20060331 |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention encompasses albumin fusion proteins. Many therapeutic proteins in their native state or when recombinantly produced are typically labile mols. exhibiting short shelf-lives, particularly when formulated in aqueous solns.; fusions of the therapeutic protein with human serum albumin have a longer serum half-life and/or stabilized activity in solution (or in a pharmaceutical composition) in vitro and/or in vivo than the corresponding unfused therapeutic mols. Thus, albumin fusion proteins are provided comprising interferon β, interferon α2, insulin, bone morphogenetic protein 9, glucagon-like peptide-I(7-36), a hybrid interferon A/D, and exendin 4. Nucleic acid mols. encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Addnl. the present invention encompasses pharmaceutical compns. comprising albumin fusion proteins and methods of treating or preventing diseases, disorders or conditions related to diabetes mellitus using albumin fusion proteins of the invention.

OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

L6 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1999:566074 CAPLUS

DOCUMENT NUMBER: 131:194807

TITLE: Insulinotropic N-terminally truncated GLP-1 lipophilic derivatives with protracted action

INVENTOR(S): Knudsen, Liselotte Bjerre; Huusfeldt, Per Olaf

PATENT ASSIGNEE(S): Novo Nordisk A/s, Den.

SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9943705 | A1 | 19990902 | WO 1999-DK81 | 19990225 |

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,

TR, TT, UA, UG, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| AU 9926105 | A | 19990915 | AU 1999-26105 | | 19990225 |
| EP 1056774 | A1 | 20001206 | EP 1999-906075 | | 19990225 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | | |
| JP 2002508162 | T | 20020319 | JP 2000-533455 | | 19990225 |
| PRIORITY APPLN. INFO.: | | | DK 1998-264 | A | 19980227 |
| | | | DK 1998-509 | A | 19980408 |
| | | | WO 1999-DK81 | W | 19990225 |

OTHER SOURCE(S): MARPAT 131:194807

AB The present invention relates to N-terminally truncated derivs. of human glucagon-like peptide-1 (GLP-1) and analogs thereof having a protracted profile of action, as well as the use of such derivs. in pharmaceutical compns. for the treatment of obesity, insulin dependent or non-insulin dependent diabetes mellitus. The GLP-1 derivs. have a lipophilic substituent attached to at least one amino acid residue.

OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1994:580232 CAPLUS
DOCUMENT NUMBER: 121:180232
ORIGINAL REFERENCE NO.: 121:32751a,32754a
TITLE: Preparation of glucagon-like peptide and insulinotropin derivatives for treating type II diabetes.
INVENTOR(S): Andrews, Glenn C.; Daumy, Gaston O.; Francoeur, Michael L.; Larson, Eric R.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9325579 | A1 | 19931223 | WO 1993-US3388 | 19930414 |
| W: AU, BR, CA, CZ, DE, JP, KR, NO, NZ, PL, RU, SK, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| AU 9340275 | A | 19940104 | AU 1993-40275 | 19930414 |
| AU 671117 | B2 | 19960815 | | |
| EP 646128 | A1 | 19950405 | EP 1993-909505 | 19930414 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |
| JP 07504679 | T | 19950525 | JP 1993-501448 | 19930414 |
| JP 2575298 | B2 | 19970122 | | |
| BR 9306551 | A | 19980915 | BR 1993-6551 | 19930414 |
| PL 176007 | B1 | 19990331 | PL 1993-306766 | 19930414 |
| RU 2128663 | C1 | 19990410 | RU 1994-46251 | 19930414 |
| EP 969016 | A2 | 20000105 | EP 1999-110184 | 19930414 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE | | | | |
| CA 2138161 | C | 20031021 | CA 1993-2138161 | 19930414 |
| IL 120890 | A | 20000831 | IL 1993-120890 | 19930607 |
| HU 64367 | A2 | 19931228 | HU 1993-1739 | 19930614 |
| CN 1085913 | A | 19940427 | CN 1993-108718 | 19930614 |
| CN 1057098 | C | 20001004 | | |
| NO 9404853 | A | 19941214 | NO 1994-4853 | 19941214 |

PRIORITY APPLN. INFO.: US 1992-899073 A1 19920615
EP 1993-909505 A3 19930414
WO 1993-US3388 A 19930414
IL 1993-105928 A3 19930607

OTHER SOURCE(S): MARPAT 121:180232

AB H2NWCO2H (W = His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly, His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg), and derivs. thereof, having pI ≤4 or ≥7, were prepared having insulinotropic activity (no data). Thus, H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-Arg-NH2 was prepared by solid phase synthesis using BOC-protected amino acids on benzhydrylamine resin. The invention also relates to new uses of certain known derivs. of insulinotropin and truncated insulinotropin to enhance insulin action in a mammal by iontophoretic administration of such derivs.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1991:1520 CAPLUS

DOCUMENT NUMBER: 114:1520

ORIGINAL REFERENCE NO.: 114:327a,330a

TITLE: Cloning of complementary DNAs encoding islet amyloid polypeptide, insulin, and glucagon precursors from a new world rodent, the degu, Octodon degus

AUTHOR(S): Nishi, Masahiro; Steiner, Donald F.

CORPORATE SOURCE: Howard Hughes Med. Inst., Univ. Chicago, Chicago, IL, 60637, USA

SOURCE: Molecular Endocrinology (1990), 4(8), 1192-8
CODEN: MOENEN; ISSN: 0888-8809

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The degu, Octodon degus, is a South American hystricomorph rodent that is of interest because it develops spontaneous diabetes mellitus and has been found to have islet amyloidosis. To help clarify these problems cDNAs encoding islet amyloid polypeptide (IAPP), insulin, and glucagon precursors were cloned from this species. The predicted amino acid sequence of degu IAPP is very similar to that of nonamyloid-forming guinea pig IAPP. In contrast, degu insulin and the C-terminal region of degu glucagon are highly divergent from those of other mammals, as is also the case in the guinea pig, suggesting the existence of some form of pos. evolutionary pressure on these hormones of carbohydrate metabolism in the hystricomorph rodents.

OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)

=> d ibib hitseq 28

L6 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1991:1520 CAPLUS

DOCUMENT NUMBER: 114:1520

ORIGINAL REFERENCE NO.: 114:327a,330a

TITLE: Cloning of complementary DNAs encoding islet amyloid polypeptide, insulin, and glucagon precursors from a new world rodent, the degu, Octodon degus

AUTHOR(S): Nishi, Masahiro; Steiner, Donald F.

CORPORATE SOURCE: Howard Hughes Med. Inst., Univ. Chicago, Chicago, IL,

60637, USA
SOURCE: Molecular Endocrinology (1990), 4(8), 1192-8
CODEN: MOENEN; ISSN: 0888-8809
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 130589-22-9 130589-23-0
RL: PRP (Properties)
(amino acid sequence of)
RN 130589-22-9 CAPLUS
CN Glucagon, prepro- (Octodon degus) (9CI) (CA INDEX NAME)

SEQ 1 MKSIYFVAGL FVMLVQGSWQ HPLQDTEEKP RSFSTSQTDL LDDPDQMNED
51 KRHSQGTFTS DYSKFLDTRR AQDFLDWLKN TKRNRNEIAK RHDEFERHAE
101 GTFTSDVSSY LEGQAAKEFI AWLVKGRGRR DFPEEVTIVE ELRRRHADGS
151 FSDEMNTVLD HLATKDFINW LIQTKITDRK

RN 130589-23-0 CAPLUS
CN Glucagon, pro- (Octodon degus) (9CI) (CA INDEX NAME)

SEQ 1 HPLQDTEEKP RSFSTSQTDL LDDPDQMNED KRHSQGTFTS DYSKFLDTRR
51 AQDFLDWLKN TKRNRNEIAK RHDEFERHAE GTFTSDVSSY LEGQAAKEFI
101 AWLVKGRGRR DFPEEVTIVE ELRRRHADGS FSDEMNTVLD HLATKDFINW
151 LIQTKITDRK

OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (23 CITINGS)

=> d ibib hitseq 27

L6 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1994:580232 CAPLUS
DOCUMENT NUMBER: 121:180232
ORIGINAL REFERENCE NO.: 121:32751a,32754a
TITLE: Preparation of glucagon-like peptide and insulinotropin derivatives for treating type II diabetes.
INVENTOR(S): Andrews, Glenn C.; Daumy, Gaston O.; Francoeur, Michael L.; Larson, Eric R.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9325579 | A1 | 19931223 | WO 1993-US3388 | 19930414 |
| W: AU, BR, CA, CZ, DE, JP, KR, NO, NZ, PL, RU, SK, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| AU 9340275 | A | 19940104 | AU 1993-40275 | 19930414 |
| AU 671117 | B2 | 19960815 | | |
| EP 646128 | A1 | 19950405 | EP 1993-909505 | 19930414 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE | | | | |

| | | | | | |
|---|---|---|---|---|---|
| JP 07504679 | T | 19950525 | JP 1993-501448 | | 19930414 |
| JP 2575298 | B2 | 19970122 | | | |
| BR 9306551 | A | 19980915 | BR 1993-6551 | | 19930414 |
| PL 176007 | B1 | 19990331 | PL 1993-306766 | | 19930414 |
| RU 2128663 | C1 | 19990410 | RU 1994-46251 | | 19930414 |
| EP 969016 | A2 | 20000105 | EP 1999-110184 | | 19930414 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE | | | | | |
| CA 2138161 | C | 20031021 | CA 1993-2138161 | | 19930414 |
| IL 120890 | A | 20000831 | IL 1993-120890 | | 19930607 |
| HU 64367 | A2 | 19931228 | HU 1993-1739 | | 19930614 |
| CN 1085913 | A | 19940427 | CN 1993-108718 | | 19930614 |
| CN 1057098 | C | 20001004 | | | |
| NO 9404853 | A | 19941214 | NO 1994-4853 | | 19941214 |
| PRIORITY APPLN. INFO.: | | | US 1992-899073 | A1 | 19920615 |
| | | | EP 1993-909505 | A3 | 19930414 |
| | | | WO 1993-US3388 | A | 19930414 |
| | | | IL 1993-105928 | A3 | 19930607 |

OTHER SOURCE(S): MARPAT 121:180232

IT 157507-31-8DP, resin bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for drug for enhancing insulin action)

RN 157507-31-8 CAPLUS

CN Glucagon-like peptide 1 (Rana catesbeiana), 3-L-glutamic acid-10-L-valine-16-glycine-17-L-glutamine-23-L-isoleucine-24-L-alanine-27-L-valine-31-glycine-32-L-argininamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GR

Absolute stereochemistry.

















IT 157507-31-8P 157569-66-9DP, succinoylated
157569-66-9P 157629-57-7P 157629-58-8P
157629-61-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for enhancing insulin action)

RN 157507-31-8 CAPLUS

CN Glucagon-like peptide 1 (Rana catesbeiana), 3-L-glutamic acid-10-L-valine-16-glycine-17-L-glutamine-23-L-isoleucine-24-L-alanine-27-L-valine-31-glycine-32-L-argininamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GR

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C




PAGE 1-D





RN 157569-66-9 CAPLUS
CN 7-36-Glucagon-like peptide 1 (Octodon degus), 36a-glycine-36b-L-arginine- (9CI) (CA INDEX NAME)

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GR

Absolute stereochemistry.





PAGE 1-B



PAGE 1-C



PAGE 1-D




PAGE 1-E




PAGE 2-B



PAGE 2-C



RN 157569-66-9 CAPLUS
CN 7-36-Glucagon-like peptide 1 (Octodon degus), 36a-glycine-36b-L-arginine- (9CI) (CA INDEX NAME)

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GR

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D




PAGE 1-E




PAGE 2-B






RN 157629-57-7 CAPLUS
CN 7-36-Glucagon-like peptide 1 (Octodon degus), 36a-glycine-36b-L-arginine-36c-L-arginine- (9CI) (CA INDEX NAME)

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GRR

RN 157629-58-8 CAPLUS
CN Glucagon-like peptide 1 (Rana catesbeiana), 3-L-glutamic acid-10-L-valine-16-glycine-17-L-glutamine-23-L-isoleucine-24-L-alanine-27-L-valine-31-glycine-32-L-arginine-32a-L-argininamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GRR

RN 157629-61-3 CAPLUS
CN Glucagon-like peptide 1 (Rana catesbeiana), N-(3-carboxy-1-oxopropyl)-3-L-glutamic acid-10-L-valine-16-glycine-17-L-glutamine-20-[N6-(3-carboxy-1-oxopropyl)-L-lysine]-23-L-isoleucine-24-L-alanine-27-L-valine-28-[N6-(3-carboxy-1-oxopropyl)-L-lysine]-31-glycine-32-L-arginine- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 HAEGTFTSDV SSYLEGQAAK EFIAWLVKGR GR

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> l2 and (diabetes or hyperglycemia or stroke)
73 L2
173773 DIABETES
28634 HYPERGLYCEMIA
35 HYPERGLYCEMIAS
28653 HYPERGLYCEMIA (HYPERGLYCEMIA OR HYPERGLYCEMIAS)
46954 STROKE
3029 STROKES
48621 STROKE (STROKE OR STROKES)
L7 28 L2 AND (DIABETES OR HYPERGLYCEMIA OR STROKE)

=>

=> d ibib hitseq 26

L7 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1999:566074 CAPLUS
DOCUMENT NUMBER: 131:194807
TITLE: Insulinotropic N-terminally truncated GLP-1 lipophilic derivatives with protracted action
INVENTOR(S): Knudsen, Liselotte Bjerre; Huusfeldt, Per Olaf
PATENT ASSIGNEE(S): Novo Nordisk A/s, Den.
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 9943705 | A1 | 19990902 | WO 1999-DK81 | 19990225 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW | | | | |
| RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| AU 9926105 | A | 19990915 | AU 1999-26105 | 19990225 |
| EP 1056774 | A1 | 20001206 | EP 1999-906075 | 19990225 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI | | | | |
| JP 2002508162 | T | 20020319 | JP 2000-533455 | 19990225 |

| PRIORITY APPLN. INFO.: | | |
|---|---|---|
| DK 1998-264 | A | 19980227 |
| DK 1998-509 | A | 19980408 |
| WO 1999-DK81 | W | 19990225 |

OTHER SOURCE(S): MARPAT 131:194807
IT 240497-60-3DP, lipophilic derivs. 240497-61-4DP, lipophilic derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of insulinotropic GLP-1 lipophilic derivs. with protracted action)
RN 240497-60-3 CAPLUS
CN L-Arginine, L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginylglycyl- (9CI) (CA INDEX NAME)

SEQ 1 AEGTFTSDVS SYLEGQAAKE FIAWLVKGRG R

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 2-C

RN 240497-61-4 CAPLUS
CN L-Arginine, L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-α-aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-

leucyl-L-α-glutamylglycyl-L-glutaminyl-L-alanyl-L-alanyl-L-lysyl-L-α-glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-lysylglycyl-L-arginylglycyl-L-arginyl- (9CI) (CA INDEX NAME)

SEQ 1 AEGTFTSDVS SYLEGQAAKE FIAWLVKGRG RR

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D




PAGE 2-A




PAGE 2-B




PAGE 2-C







OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff h

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 138.54 | 363.58 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -23.80 | -23.80 |

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:50:05 ON 07 MAR 2010